The overall goal of the proposed research is to develop orally active inhibitors of myeloperoxidase MPO as a treatment forAlzheimer's disease. MPO is an abundant enzyme in leukocytes but its expression can be induced in astrocytes in Alzheimer's disease. This abnormal expression of MPO can lead to the oxidation of lipids and proteins leading to tissue damage and cell death resulting in loss of memory. A potent and safe inhibitor of MPO could be helpful in the treatment of Alzheimer's disease. We have developed novel mouse model to evaluate the role of MPO in Alzheimer's disease.
In Specific Aim 1 We propose to improve the potency of hits identified in a screen looking for inhibitors of MPO.
In Specific Aim 2 we propose to test several of the MPO inhibitors in a mouse model of Alzheimer's disease. The mice will be evaluated using both biochemical and behavioral/cognitive tests.

Public Health Relevance

Myeloperoxidase is recognized as an important causative contributory agent in inflammatory diseases including Alzheimer's disease. An inhibitor of myeloperoxidase would provide a novel therapeutic agent that could be used to lower the level of oxidative damage that occurs in Alzheimer's disease. The experiments outlined in this Phase I SBIR application will help set the stage for the development of a novel and safe myeloperoxidase inhibitor for clinical use.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AG040935-01A1
Application #
8315644
Study Section
Special Emphasis Panel (ZRG1-ETTN-P (11))
Program Officer
Refolo, Lorenzo
Project Start
2012-07-01
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$255,109
Indirect Cost
Name
Torrey Pines Pharmaceuticals, Inc.
Department
Type
DUNS #
809869840
City
Del Mar
State
CA
Country
United States
Zip Code
92014